Elucid Raises $27 Million To Diagnose Heart Disease With AI
Elucid, a company offering machine learning powered heart disease diagnosis tools, has raised a total of $27 million through a Series B funding round.
Created on June 24|Last edited on June 24
Comment
Heart disease is the leading cause of death globally, so advances in accurate diagnosis and treatment are imperative if doctors are to save countless lives. Machine learning already supports so many fields of medical research and diagnosis, so why not cardiovascular medicine as well?
Elucid is a company that offers machine learning solutions for doctors working to screen patients for heart disease. With algorithms built to accurately analyze artery wall tissues and plaques, their technology can help determine the source of chest pains and alert doctors of early-stage heart disease so they can treat the patients quickly and effectively.
Who's funding Elucid and where's the money going?
Elucid has announced the completion of a Series B funding round for a total amount of $27 million. The funding round was apparently led by an "undisclosed strategic investor" but additional participants aren't staying so secretive: BioVision Ventures, MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners.
The collected money is said simply to be for expanding Elucid's commercial reach - to make Elucid's AI technology more broadly available to doctors treating heart disease.
Find out more
Add a comment
Tags: ML News
Iterate on AI agents and models faster. Try Weights & Biases today.